Patents Assigned to Merck Sharp & Dohme
  • PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS
    Publication number: 20220064147
    Abstract: The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
    Type: Application
    Filed: December 13, 2019
    Publication date: March 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Antonella Converso, Abdellatif El Marrouni, Ashley Forster, Jessica L. Frie, David N. Hunter, Scott D. Kuduk, Helen J. Mitchell, Philippe Nantermet, Deyou Sha, William Daniel Shipe, Cheng Wang, Deping Wang
  • METHODS OF USING BUTYROPHILIN ANTIBODIES FOR TREATING HIV INFECTION
    Publication number: 20220064291
    Abstract: The present invention relates to methods for treating individuals infected with the human immunodeficiency virus (HIV) comprising administering to the subject with an antibody to Butyrophilin that reactivates HIV from latency and/or activates CD4+ T cells.
    Type: Application
    Filed: December 17, 2019
    Publication date: March 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bonnie Jean Howell, Hsien-Wei Yvonne Meng, Morgan Ann Monslow, Hussam Hisham Shaheen, Sai Vikram Vemula
  • SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING
    Publication number: 20220056045
    Abstract: The instant invention is related to a novel solid form of ceftolozane sulfate (the DMAc solvate of ceftolozane sulfate (Form 3)), compositions comprising ceftolozane sulfate DMAc solvate (Form 3), synthesis of Form 3 and an improved crystallization process using Form 3 to prepare ceftolozane sulfate Form 2. Novel compositions also include ceftolozane sulfate solid Form 3 and/or other crystalline and amorphous solid forms of ceftolozane.
    Type: Application
    Filed: June 1, 2017
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kevin Matthew Maloney, Eric M. Sirota, Richard J. Varsolona, Donald R. Gauthier, Jr., Hong Ren
  • BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS
    Publication number: 20220056017
    Abstract: The present invention is directed to bicyclo[4.1.0]heptane pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Stephane L. BOGEN, Dane James CLAUSEN, Deodial Guy GUIADEEN, Jinsong HAO, Shishi LIN, Michael T. RUDD, Lan WEI, Li XIAO, Dexi YANG
  • ARGINASE INHIBITORS AND METHODS OF USE
    Publication number: 20220056051
    Abstract: Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.
    Type: Application
    Filed: December 13, 2019
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Abdelghani Abe Achab, Matthew L. Childers, Jared N. Cumming, Symon Gathiaka, Charles A. Lesburg, Derun Li, Min Lu, Matthew J. Mitcheltree, Anandan Palani, Rachel L. Palte, Hongjun Zhang
  • NOVEL CRYSTALLINE FORMS OF AN NRTTI COMPOUND
    Publication number: 20220056067
    Abstract: The present disclosure provides novel anhydrate crystalline Forms 1 and 4 of 4?-Ethynyl-2-fluoro-2?-deoxyadenosine and pharmaceutical compositions thereof, each of which may be useful for the inhibition of HIV reverse transcriptase, the treatment or prophylaxis of HIV infection and/or the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC.
    Type: Application
    Filed: December 16, 2019
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daniel Skomski, Yongchao Su, Wei Xu, Marko Cubrovic
  • TREATING INFECTIONS WITH CEFTOLOZANE/TAZOBACTAM IN SUBJECTS HAVING IMPAIRED RENAL FUNCTION
    Publication number: 20220054460
    Abstract: Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection.
    Type: Application
    Filed: February 2, 2021
    Publication date: February 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gopal KRISHNA, Gurudatt A. CHANDORKAR, Elham HERSHBERGER, Benjamin MILLER, Alan XIAO
  • PD1 AND/OR LAG3 BINDERS
    Publication number: 20220041727
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: October 8, 2021
    Publication date: February 10, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
    Publication number: 20220040184
    Abstract: In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): and, and pharmaceutically acceptable salts thereof, wherein, R1, n, R2, and R3 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.
    Type: Application
    Filed: November 15, 2019
    Publication date: February 10, 2022
    Applicant: Merck Sharp Dohme Corp.
    Inventors: Zachary G. Brill, Amjad Ali, Jared Cumming, Duane DeMong, Qiaolin Deng, Gioconda V. Gallo-Etienne, Thomas H. Graham, Rongze Kuang, Matthew A. Larsen, Yeon-Hee Lim, Kun Liu, Umar Faruk Mansoor, Jesus Moreno, Brandon A. Vara, Huijun Wang, Yonglian Zhang
  • Cyclic Di-Nucleotide Compounds as STING Agonists
    Publication number: 20220033431
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Application
    Filed: December 2, 2019
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Wonsuk Chang, Jared N. Cumming, Hong Liu, Benjamin Wesley Trotter
  • METHOD FOR IDENTIFYING HIGH AFFINITY MONOCLONAL ANTIBODY HEAVY AND LIGHT CHAIN PAIRS FROM HIGH THROUGHPUT SCREENS OF B-CELL AND HYBRIDOMA LIBRARIES
    Publication number: 20220034902
    Abstract: A method is described for identifying high affinity monoclonal antibody heavy and light chain pairs from high throughput screens of antibody producing cell libraries such as B-cell and hybridoma libraries. Specifically, the method relates to application of reversed immunocapture and high resolution tandem mass spectrometry for the identification of heavy and light chain pairs of binding antibodies obtained from high throughput screens of antibody producing cell libraries.
    Type: Application
    Filed: December 6, 2019
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Eberhard Durr, Yaping Liu, Zhifeng Chen, Arthur Fridman
  • PNEUMOCOCCAL CONJUGATE VACCINE FORMULATIONS
    Publication number: 20220031837
    Abstract: The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.
    Type: Application
    Filed: August 26, 2021
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: William J. Smith, Cecilia Giovarelli, Denise K. Nawrocki
  • EXPRESSION VECTORS FOR EUKARYOTIC EXPRESSION SYSTEMS
    Publication number: 20220033845
    Abstract: The invention provides expression vectors for expressing recombinant proteins (e.g., biologics) in mammalian cells. Also provided are host cells comprising the expression vectors, methods of producing the recombinant proteins, and methods of propagating the expression vectors.
    Type: Application
    Filed: September 23, 2019
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Zhimei Du, Bo Jiang, Xiaoyan Tang
  • ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
    Publication number: 20220033496
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.
    Type: Application
    Filed: June 3, 2021
    Publication date: February 3, 2022
    Applicants: Merck Sharp & Dohme Corp., Agenus Inc.
    Inventors: Milan BLANUSA, Barbara JOYCE-SHAIKH, Andrea Claudia SCHUSTER, Kornelia SCHULTZE, Luis A. ZUNIGA
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220033497
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • Cyclic Di-Nucleotide Compounds as STING Agonists
    Publication number: 20220033435
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds (I).
    Type: Application
    Filed: December 2, 2019
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Wonsuk Chang, Jared N. Cumming, Hong Liu, Benjamin Wesley Trotter
  • COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR FOR TREATING CANCER
    Publication number: 20220023285
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
    Type: Application
    Filed: October 15, 2021
    Publication date: January 27, 2022
    Applicants: MERCK SHARP & DOHME CORP., EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Andrew Evan DENKER, Yu KATO, Kimiyo TABATA, Yusaku HORI
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220025042
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • Cyclic Di-Nucleotide Compounds as STING Agonists
    Publication number: 20220024964
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds (I).
    Type: Application
    Filed: December 2, 2019
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Wonsuk Chang, Jared N. Cumming, Hong Liu, Benjamin Wesley Trotter
  • CELL-BASED BIOIDENTITY TEST FOR INSULIN
    Publication number: 20220026414
    Abstract: A functional cell-based assay for use as a bioidentity assay for insulin or insulin analogs is described. The assay may be used as a replacement of the rabbit blood sugar method disclosed in USP<121> Insulin Assays.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventor: Junming Yie